Your browser doesn't support javascript.
loading
Incidences of colorectal adenomas and cancers under colonoscopy surveillance suggest an accelerated "Big Bang" pathway to CRC in three of the four Lynch syndromes.
Møller, Pål; Haupt, Saskia; Ahadova, Aysel; Kloor, Matthias; Sampson, Julian R; Sunde, Lone; Seppälä, Toni; Burn, John; Bernstein, Inge; Capella, Gabriel; Evans, D Gareth; Lindblom, Annika; Winship, Ingrid; Macrae, Finlay; Katz, Lior; Laish, Ido; Vainer, Elez; Monahan, Kevin; Half, Elizabeth; Horisberger, Karoline; da Silva, Leandro Apolinário; Heuveline, Vincent; Therkildsen, Christina; Lautrup, Charlotte; Klarskov, Louise L; Cavestro, Giulia Martina; Möslein, Gabriela; Hovig, Eivind; Dominguez-Valentin, Mev.
  • Møller P; Department of Tumour Biology, Institute of Cancer Research, The Norwegian Radium Hospital, Oslo, 0379, Norway. moller.pal@gmail.com.
  • Haupt S; Engineering Mathematics and Computing Lab (EMCL), Interdisciplinary Center for Scientific Computing (IWR), Heidelberg University, Heidelberg, Germany.
  • Ahadova A; Data Mining and Uncertainty Quantification (DMQ), Heidelberg Institute for Theoretical Studies (HITS), Heidelberg, Germany.
  • Kloor M; Department of Applied Tumour Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Sampson JR; Clinical Cooperation Unit Applied Tumour Biology, German Cancer Research Centre (DKFZ), Heidelberg, Germany.
  • Sunde L; Department of Applied Tumour Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Seppälä T; Clinical Cooperation Unit Applied Tumour Biology, German Cancer Research Centre (DKFZ), Heidelberg, Germany.
  • Burn J; Institute of Medical Genetics, Division of Cancer and Genetics, Cardiff University School of Medicine, Heath Park, Cardiff, CF14 4XN, UK.
  • Bernstein I; Department of Clinical Genetics, Aalborg University Hospital, Aalborg, 9000, Denmark.
  • Capella G; Department of Biomedicine, Aarhus University, Aarhus, DK-8000, Denmark.
  • Evans DG; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
  • Lindblom A; Faculty of Medicine and Health Technology, Tays Cancer Center, Tampere University, Tampere University Hospital, Tampere, Finland.
  • Winship I; Department of Gastrointestinal Surgery, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland.
  • Macrae F; Applied Tumour Genomics, Research Program Unit, University of Helsinki, Helsinki, Finland.
  • Katz L; Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK.
  • Laish I; Dept. of Quality and Coherence, Aalborg University Hospital, Aalborg, 9000, Denmark.
  • Vainer E; Department of Clinical Medicine, Aalborg University Hospital, Aalborg University, Aalborg, 9100, Denmark.
  • Monahan K; Hereditary Cancer Program, Institut Català d'Oncologia-IDIBELL, L; Hospitalet de Llobregat, Barcelona, 08908, Spain.
  • Half E; Manchester Centre for Genomic Medicine, Division of Evolution, Infection and Genomic Sciences, University of Manchester, Manchester University NHS Foundation Trust, Manchester, M13 9WL, UK.
  • Horisberger K; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, 171 76, Sweden.
  • da Silva LA; Dept Clinical Genetics, Karolinska University Hospital, Solna, Sweden.
  • Heuveline V; Genomic Medicine, The Royal Melbourne Hospital, Melbourne, Australia.
  • Therkildsen C; Department of Medicine, University of Melbourne, Melbourne, Australia.
  • Lautrup C; Department of Medicine, University of Melbourne, Melbourne, Australia.
  • Klarskov LL; Department of Gastroenterology, Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Hadassah, Israel.
  • Cavestro GM; Gastroenerolgy institute, Sheba medical center and Faculty of medicine Tel Aviv university, Tel Aviv, Israel.
  • Möslein G; Department of Gastroenterology, Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Hadassah, Israel.
  • Hovig E; Lynch Syndrome & Family Cancer Clinic, Centre for Familial Intestinal Caner, St Mark's Hospital, London, UK.
  • Dominguez-Valentin M; Gastrointestinal Cancer Prevention Unit, Gastroenterology Department, Rambam Health Care Campus, Haifa, Israel.
Hered Cancer Clin Pract ; 22(1): 6, 2024 May 13.
Article en En | MEDLINE | ID: mdl-38741120
ABSTRACT

BACKGROUND:

Colorectal cancers (CRCs) in the Lynch syndromes have been assumed to emerge through an accelerated adenoma-carcinoma pathway. In this model adenomas with deficient mismatch repair have an increased probability of acquiring additional cancer driver mutation(s) resulting in more rapid progression to malignancy. If this model was accurate, the success of colonoscopy in preventing CRC would be a function of the intervals between colonoscopies and mean sojourn time of detectable adenomas. Contrary to expectations, colonoscopy did not decrease incidence of CRC in the Lynch syndromes and shorter colonoscopy intervals have not been effective in reducing CRC incidence. The prospective Lynch Syndrome Database (PLSD) was designed to examine these issues in carriers of pathogenic variants of the mis-match repair (path_MMR) genes. MATERIALS AND

METHODS:

We examined the CRC and colorectal adenoma incidences in 3,574 path_MLH1, path_MSH2, path_MSH6 and path_PMS2 carriers subjected to regular colonoscopy with polypectomy, and considered the results based on sojourn times and stochastic probability paradigms.

RESULTS:

Most of the path_MMR carriers in each genetic group had no adenomas. There was no association between incidences of CRC and the presence of adenomas. There was no CRC observed in path_PMS2 carriers.

CONCLUSIONS:

Colonoscopy prevented CRC in path_PMS2 carriers but not in the others. Our findings are consistent with colonoscopy surveillance blocking the adenoma-carcinoma pathway by removing identified adenomas which might otherwise become CRCs. However, in the other carriers most CRCs likely arised from dMMR cells in the crypts that have an increased mutation rate with increased stochastic chaotic probabilities for mutations. Therefore, this mechanism, that may be associated with no or only a short sojourn time of MSI tumours as adenomas, could explain the findings in our previous and current reports.
Palabras clave